![]() |
|
|
Forward to a colleague |
||
Access Full Stories Recipharm has come to rescue of UK-based Ashton Pharma, which has been nervously awaiting to discover its fate, having spent five months in administration after its former owners Inyx Inc. suffered major financial... Read Boehringer Ingelheim takes on prefilled syringes Boehringer Ingelheim has added to its contract services with the manufacture, fill and finish capacity for drugs in prefilled syringes... Read FMC improves on existing excipients FMC BioPolymer has introduced two new excipient products to the pharma market - the first in two years... Read Pharmaceutical patent round-up In-PharmaTechnologist.com brings you an update of pharmaceutical patent litigations... Read Take off immune system brake to improve cancer vaccines The discovery of a new molecule that can act as a brake for the immune system could lead to new therapies for cancer and autoimmune diseases such as diabetes... Read |
||||||||||||||
All News Headlines for: November | October | September |
||||||||||||||
Upgrading pharmaceutical production with new bulk excipients Are you looking for a new bulk excipient to facilitate wet granulation or compaction? The new galenIQ™ 800 series offers tailor-made powder grades to upgrade your agglomeration process... Click Here | ||||||||||||||
|
Related Industry News Mr Gene designs and orders constructs in minutes Geneart has launched the first fully on-line gene construct design and ordering system, dubbed Mr Gene, which is targeting the emerging 'low-price' segment of the synthetic biology market... Read New research offers CRO market snapshot New research from Frost & Sullivan provides a snapshot of biopharma spending trends on contract research organisations (CROs), along with forecasts for industry growth... Read Evolution study finds 300 new genes A supercomputer designed to root out genes that have been conserved over millions of years of evolution has discovered 300 new human genes... Read Covance rescues Eli Lilly's forgotten facility Covance has acquired a partially constructed facility from Eli Lilly and plans to invest $175m (€118m) to convert it into a drug development laboratory to meet demand from its biopharmaceutical customers... Read
|
||||||||||||||
|
|||||
Forward to a colleague |
|||||
To continue to receive this newsletter in your inbox, please add newsletter@In-PharmaTechnologist.com to your address book |
||
Update preferences | Change your email address | Unsubscribe |
||
Contact us: Advertising | Recruitment | Privacy policy | Terms & conditions | Feedback |
||
| © 2007 - Decision News Media S.A.S - All Rights Reserved Le Belem - 355, rue Vendemiaire - 34000 Montpellier - France http://www.decisionnewsmedia.com |
||